These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 7677964)

  • 1. Reversing ontogeny.
    Bunn HF
    N Engl J Med; 1993 Jan; 328(2):129-31. PubMed ID: 7677964
    [No Abstract]   [Full Text] [Related]  

  • 2. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders.
    Perrine SP; Ginder GD; Faller DV; Dover GH; Ikuta T; Witkowska HE; Cai SP; Vichinsky EP; Olivieri NF
    N Engl J Med; 1993 Jan; 328(2):81-6. PubMed ID: 7677966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
    Pearson HA
    Adv Pediatr; 1996; 43():309-34. PubMed ID: 8794181
    [No Abstract]   [Full Text] [Related]  

  • 4. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
    Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders.
    Perrine SP; Olivieri NF; Faller DV; Vichinsky EP; Dover GJ; Ginder GD
    Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):67-71. PubMed ID: 7508690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies.
    Sher GD; Ginder GD; Little J; Yang S; Dover GJ; Olivieri NF
    N Engl J Med; 1995 Jun; 332(24):1606-10. PubMed ID: 7753139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
    N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia?
    Fathallah H; Sutton M; Atweh GF
    Ann N Y Acad Sci; 2005; 1054():228-37. PubMed ID: 16339670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic reactivation of fetal haemoglobin.
    Olivieri NF; Weatherall DJ
    Hum Mol Genet; 1998; 7(10):1655-8. PubMed ID: 9735388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic induction of fetal hemoglobin synthesis: cellular and molecular mechanisms.
    Yang YM; Pace B
    Pediatr Pathol Mol Med; 2001; 20(1):87-106. PubMed ID: 12673846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
    Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
    Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
    Adekile A; Menzel S; Gupta R; Al-Sharida S; Farag A; Haider M; Akbulut N; Mustafa N; Thein SL
    Am J Hematol; 2015 Jul; 90(7):E138-9. PubMed ID: 25851995
    [No Abstract]   [Full Text] [Related]  

  • 13. Reactivation of fetal hemoglobin in patients with beta-thalassemia.
    Olivieri NF
    Semin Hematol; 1996 Jan; 33(1):24-42. PubMed ID: 8714583
    [No Abstract]   [Full Text] [Related]  

  • 14. Induction of fetal hemoglobin in sickle cell disease.
    Bunn HF
    Blood; 1999 Mar; 93(6):1787-9. PubMed ID: 10068648
    [No Abstract]   [Full Text] [Related]  

  • 15. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
    Borg J; Phylactides M; Bartsakoulia M; Tafrali C; Lederer C; Felice AE; Papachatzopoulou A; Kourakli A; Stavrou EF; Christou S; Hou J; Karkabouna S; Lappa-Manakou C; Ozgur Z; van Ijcken W; von Lindern M; Grosveld FG; Georgitsi M; Kleanthous M; Philipsen S; Patrinos GP
    Pharmacogenomics; 2012 Oct; 13(13):1487-500. PubMed ID: 23057549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations in protein-DNA interactions in the gamma-globin gene promoter in response to butyrate therapy.
    Ikuta T; Kan YW; Swerdlow PS; Faller DV; Perrine SP
    Blood; 1998 Oct; 92(8):2924-33. PubMed ID: 9763579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic studies of fetal hemoglobin in the Arab-Indian haplotype sickle cell-β(0) thalassemia.
    Alsultan A; Ngo D; Bae H; Sebastiani P; Baldwin CT; Melista E; Suliman AM; Albuali WH; Nasserullah Z; Luo HY; Chui DH; Steinberg MH; Al-Ali AK
    Am J Hematol; 2013 Jun; 88(6):531-2. PubMed ID: 23483609
    [No Abstract]   [Full Text] [Related]  

  • 19. Hydroxyurea increases fetal hemoglobin production in sickle cell anemia.
    Platt OS; Orkin SH; Dover G; Beardsley GP; Miller B; Nathan DG
    Trans Assoc Am Physicians; 1984; 97():268-74. PubMed ID: 6085528
    [No Abstract]   [Full Text] [Related]  

  • 20. Hydroxyurea therapy in thalassemia.
    Loukopoulos D; Voskaridou E; Stamoulakatou A; Papassotiriou Y; Kalotychou V; Loutradi A; Cozma G; Tsiarta H; Pavlides N
    Ann N Y Acad Sci; 1998 Jun; 850():120-8. PubMed ID: 9668534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.